Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing phenotype, but further studies are required. Current acute exacerbation management strategies are based on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have been performed. Although there are no formal strategies to prevent the development of acute exacerbation, possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges limitations of the data available.

Kolb, M., Bondue, B., Pesci, A., Miyazaki, Y., Song, J., Bhatt, N., et al. (2018). Acute exacerbations of progressive-fibrosing interstitial lung diseases. EUROPEAN RESPIRATORY REVIEW, 27(150) [10.1183/16000617.0071-2018].

Acute exacerbations of progressive-fibrosing interstitial lung diseases

Pesci, A;
2018

Abstract

Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing phenotype, but further studies are required. Current acute exacerbation management strategies are based on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have been performed. Although there are no formal strategies to prevent the development of acute exacerbation, possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges limitations of the data available.
Articolo in rivista - Review Essay
Disease Progression; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Phenotype; Prognosis; Pulmonary Fibrosis; Risk Assessment; Risk Factors
English
2018
27
150
180071
open
Kolb, M., Bondue, B., Pesci, A., Miyazaki, Y., Song, J., Bhatt, N., et al. (2018). Acute exacerbations of progressive-fibrosing interstitial lung diseases. EUROPEAN RESPIRATORY REVIEW, 27(150) [10.1183/16000617.0071-2018].
File in questo prodotto:
File Dimensione Formato  
10281-234037.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 392.79 kB
Formato Adobe PDF
392.79 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/234037
Citazioni
  • Scopus 115
  • ???jsp.display-item.citation.isi??? 102
Social impact